PROFILE |
 |
Signal Research Division wants to be the traffic cop for disease. The drug discovery firm, a subsidiary of Celgene, identifies drugs that regulate genes and the production of disease-causing proteins. Signal maps gene-regulating pathways in cells in an effort to identify molecular targets that activate or deactivate genes. The firm hopes to develop treatments that can selectively regulate the activation of these genes. Its drug discovery programs target inflammatory, cardiovascular, and neurological diseases, as well as cancer. Signal works with its parent, as well as with such partners as DuPont, Axys Pharmaceuticals, and Serono.
COMPETITION |
 |
ARIAD Pharmaceuticals, Inc. (ARIA)
Transkaryotic Therapies, Inc. (TKTX)
Vertex Pharmaceuticals Incorporated (VRTX)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
1999 Sales (mil.): 11.70
1-Yr. Sales Growth: (23.8)%
Employees: 87
Revenue per employee: $134,482.76
KEY PEOPLE |
 |
Alan J. Lewis
CEO
Bradley B. Gordon
CFO
CONTACT INFO |
 |
5555 Oberlin Dr.
San Diego, CA 92121
US
Phone: 858-558-7500
Fax: 858-558-7513
Online: Web Site
|